Leptomeningeal Disease clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
A phase 2 non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab with capecitabine for the treatment of leptomeningeal metastases in HER2-neu positive breast cancer.
San Francisco, California and other locations
Our lead scientists for Leptomeningeal Disease research studies include Michelle Melisko.